Search

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Read more

EHA Congratulates the 2021 Bilateral Collaborative Grant Winners

The Hague, April 25, 2022 –EHA congratulates four talented researchers in Hematology on their receipt of the inaugural EHA Bilateral Collaborative Grants 2021 after a rigorous selection process.

Read more

EHA Diversity, Equity, and Inclusion Award 2024

The EHA Diversity, Equity, and Inclusion (DEI) Award celebrates achievements that foster inclusivity. It recognizes efforts taken by individuals, teams, or organizations (collectively “candidate”) to promote DEI within leadership, initiatives, and overall work.

Read more

Nobel prize goes to immunotherapy researchers

October 1, Sweden - Cancer kills millions of people every year and is one of humanity’s greatest health challenges.

Read more

A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Read more

Bleeding and Thrombosis

The objectives of the SWG on ‘Bleeding and Thrombosis’ are:

To promote education in the field of blood coagulation, including mechanisms, prevention, and treatment of bleeding and thrombotic disorders.

Read more

European Affairs

Advocating & collaborating for hematologyEHA serves as the face and voice of hematology and hematology professionals in Europe.

Read more